The US Food and Drug Administration (FDA) has granted 510(k) clearance for Drawbridge Health’s OneDraw A1C Test System.
The OneDraw A1C Test System aims to collect and stabilise blood and measurement of HbA1c levels to monitor long-term control of blood sugar (glucose) in those with diabetes.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
A healthcare professional (HCP) can use OneDraw to draw blood quickly and comfortably.
Drawbridge Health CEO Lee McCracken said: “Drawbridge Health was founded with the vision and intent to categorically and positively change the nature of blood-based diagnostic testing, improving both the collection process and patient experience.
“Our 510(k) clearance is a critical milestone as we make our founding vision a reality. We look forward to making our novel technology commercially available soon.”
The small, single-use OneDraw Blood Collection Device collects and stabilises a capillary blood sample from the upper arm.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt can be placed on the skin to collect blood gently using tiny lancets with light vacuum suction. The blood sample is then stabilised and contained within a removable cartridge.
A designated certified clinical laboratory performs the OneDraw A1C Test after use of the OneDraw Blood Collection Device.
Additionally, the OneDraw Blood Collection Device optimises the blood collection process for the patient and enables conducting blood sampling anywhere.
The 510(k) clearance for the device comes after the company presented positive clinical trial data.
The data results highlighted a strong correlation in the HbA1c measurement obtained from samples collected using the OneDraw Blood Collection Device and those using venipuncture.
